Incretin Receptor Agonists Linked to Iron Deficiency; Strategies Proposed for Prevention and Management
Background
Incretin receptor agonists, including GLP-1 receptor agonists (GLP-1 RA) like semaglutide and dual GIP/GLP-1 receptor agonists like tirzepatide, have revolutionized the treatment of type 2 diabetes, overweight, and obesity. These therapies effectively promote weight loss and glycemic control, but their widespread use has unveiled emerging adverse effects. One such concern is the potential for micronutrient deficiencies, particularly iron deficiency and iron deficiency anemia (IDA), which can impact patient health and treatment adherence. Understanding the mechanisms behind this potential link is crucial for proactive clinical management.
Study Design
This review article synthesized recent preliminary observational evidence exploring the relationship between incretin receptor agonist-based therapies and the development of iron deficiency and IDA. The authors discussed potential mechanisms by which these drugs, specifically GLP-1 RAs and tirzepatide, might affect iron homeostasis. They also proposed practical strategies for clinicians to prevent and manage these nutritional complications, drawing from existing literature on dietary intake, gastrointestinal physiology, and nutrient absorption, without conducting new experimental studies or clinical trials.
Results
The review identified several potential mechanisms linking incretin receptor agonists to iron deficiency. These include inadequate dietary iron intake, primarily due to incretin receptor agonist-mediated reduction in food intake and gastrointestinal adverse effects. Patients may also experience low dietary variety, monotonous diets, and changes in food preferences. Furthermore, impairment of intestinal iron absorption is hypothesized due to delayed gastric emptying, reduced small intestinal motility, and decreased gastric acid secretion caused by incretin receptor agonists. Hypothetical mechanisms requiring further confirmation include vitamin B2 (riboflavin) deficiency and changes in gut microbiota composition. While these effects are noted:
Iron deficiency and IDA currently appear to be uncommon adverse effects of incretin receptor agonist-based therapies. However, clinicians should remain aware of their potential occurrence to ensure appropriate prevention and management.
Key Findings
- Incretin receptor agonists (GLP-1 RAs, tirzepatide) are linked to potential iron deficiency and iron deficiency anemia (IDA).
- Mechanisms include reduced dietary iron intake due to decreased appetite and GI side effects.
- Impaired intestinal iron absorption may result from delayed gastric emptying and reduced gut motility.
- Hypothesized links include
vitamin B2deficiency and altered gut microbiota composition. - Iron deficiency and IDA are currently uncommon adverse effects, but clinicians should be aware.
Why It Matters
This review highlights a critical, albeit uncommon, consideration for individuals using or prescribing incretin receptor agonists like semaglutide or tirzepatide. Proactive monitoring for iron deficiency and implementing dietary or supplemental strategies is crucial, especially for long-term users. Clinicians should counsel patients on maintaining adequate dietary iron intake and consider iron supplementation if deficiencies are identified. This insight suggests that while these peptides are highly effective for metabolic health, their impact on nutrient absorption and dietary habits necessitates a holistic approach to patient care, potentially influencing how these therapies are combined with nutritional guidance or other supplements.
incretin-receptor-agonists
glp-1-ra
tirzepatide
iron-deficiency
anemia
micronutrient-deficiency